Form 8-K Jazz Pharmaceuticals For: Jul 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Jazz Pharmaceuticals (JAZZ) PT Lowered to $174 at RBC Capital
August 1, 2024 6:26 AM EDTRBC Capital analyst Daniel Busb lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $174.00 (from $175.00) while maintaining a Outperform rating.
The analyst comments "JAZZ puts up solid 2Q commercial numbers (avoiding a guide cut as recently feared), while the removal of Vision... More
